Unicycive Therapeutics: Developing Unique, Low Pill Burden Therapeutics for Kidney Diseases
Nov. 30, 2022
A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics (NASDAQ: UNCY) is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive's current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury. Visit UNCYinfo.com to learn more.
